Pharma News, 2023

Immunotherapy, particularly CAR T-Cell treatment for cancer, is extending the lives of many patients. But sometimes the therapy randomly migrates to places it shouldn’t go, tucking into the lungs...

AbbVie ABBV announced that the FDA has approved the label expansion of its migraine drug Qulipta (atogepant) at 60mg dose to include the prevention of chronic migraine in adults. ...

Acadia’s Daybue begins commercial launch as the first approved treatment for Rett Syndrome, following a recent FDA approval.

Israeli biotech company Gamida Cell has secured approval from the US Food and Drug Administration (FDA) for Omisirge (omidubicel-onlv), an allogeneic cell therapy. ...

Agenus Inc. announced that the FDA has granted Fast Track Designation to the experimental combination of botensilimab (AGEN1181) and balstilimab (AGEN2034).  ...

After circling around the crop of biotechs ripe for a takeover, Big Pharma companies have finally decided to strike.

GSK has agreed to acquire late-stage biopharma BELLUS Health, for a total of £1.6 billion. A novel P2X3 antagonist is set to advance GSK’s respiratory pipeline as part of its planned acquisition...

Supplementation or dietary intake of omega-3 fatty acid may reduce the risk for cognitive decline.

License and development agreement with Janssen leverages Pipeline’s expertise in precision neuroregeneration and Janssen’s development experience across nervous system disorders ...

Prometheus’s PRA023 is being developed to treat Crohn’s disease, ulcerative colitis and other autoimmune conditions.

The MCG solution helps detect myocardial ischemia in patients suspected of having coronary microvascular disease.

The FDA issued a complete response letter to Eli Lilly indicating it cannot approve the company’s biologic license application seeking approval for mirikizumab as a treatment for ulcerative colit...